Vickers Venture Fund VI Pte Ltd 4
4 · Aardvark Therapeutics, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Vickers Venture Fund VI Pte Ltd
10% Owner
Transactions
- Conversion
Common Stock
2025-02-14+1,637,411→ 1,637,411 total(indirect: By Vickers Venture Fund VI Pte. Ltd.) - Conversion
Common Stock
2025-02-14+413,491→ 2,050,902 total(indirect: By Vickers Venture Fund VI Pte. Ltd.) - Conversion
Series A Convertible Preferred Stock
2025-02-14−13,875,429→ 0 total(indirect: By Vickers Venture Fund VI Pte. Ltd.)→ Common Stock (1,637,411 underlying) - Conversion
Series B Convertible Preferred Stock
2025-02-14−3,503,919→ 0 total(indirect: By Vickers Venture Fund VI Pte. Ltd.)→ Common Stock (413,491 underlying)
Footnotes (4)
- [F1]The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.
- [F2]These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI.
- [F3](Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
- [F4]The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date.